Product Information

PAXLOVID 300/150-100 MG DOSE PACK (SEVERE RENAL DOSE) is a brand product labeled by Pfizer Inc., priced at $133.5413 per EA under NDC 00069545011. Its NADAC has been published 21 times since Feb 4, 2026.

PAXLOVID 300/150-100 MG DOSE PACK (SEVERE RENAL DOSE)

nirmatrelvir and ritonavir
$133.5413per EA

Manufacturer

Pfizer Inc.

NDC

00069545011

Classification

Brand

Dosage Form

KIT

Last Updated

6/17/2026

Approval Type

New Drug (NDA)

FDA Application

NDA217188

On Market Since

1/5/2026

Price Statistics

The NADAC for PAXLOVID 300/150-100 MG DOSE PACK (SEVERE RENAL DOSE) has been published 21 times since Feb 4, 2026, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.

Current price$133.5413 per EA
All-time high$134.1575 (Jun 10, 2026)
All-time low$133.5413 (Jun 17, 2026)
52-week high$134.1575
52-week low$133.5413
Median price$134.1575
Average price$134.0988
Largest weekly change-0.5% (Jun 17, 2026)
Weeks tracked21
Tracking sinceFeb 4, 2026

Price History

1W

0.0%

1M

-0.5%

3M

-0.5%

6M

N/A

1Y

N/A

3Y

N/A

5Y

N/A

All

-0.5%

Generic Alternatives

The matcher finds 1 NADAC-published product sharing this drug's active ingredient, strength, and dosage form across 1 manufacturer (up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 63% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Lowest-Cost Alternatives

Save up to 63%

1 alternative • Same active ingredient

Frequently asked questions

What is the NADAC price of PAXLOVID 300/150-100 MG DOSE PACK (SEVERE RENAL DOSE)?

The current National Average Drug Acquisition Cost (NADAC) for PAXLOVID 300/150-100 MG DOSE PACK (SEVERE RENAL DOSE), manufactured by Pfizer Inc., is $133.5413 per EA (NDC 00069545011), effective Jun 24, 2026.

How has the price of PAXLOVID 300/150-100 MG DOSE PACK (SEVERE RENAL DOSE) changed over time?

Over the history we have for it, the NADAC for PAXLOVID 300/150-100 MG DOSE PACK (SEVERE RENAL DOSE) has held within roughly two percent of its current level. It has been tracked across 21 weekly CMS publications since Feb 4, 2026.

What are the highest and lowest recorded NADAC prices for PAXLOVID 300/150-100 MG DOSE PACK (SEVERE RENAL DOSE)?

Since Feb 4, 2026, the NADAC for PAXLOVID 300/150-100 MG DOSE PACK (SEVERE RENAL DOSE) has ranged from a low of $133.5413 (Jun 17, 2026) to a high of $134.1575 (Jun 10, 2026), with a median of $134.1575 per EA.

Are there cheaper alternatives to PAXLOVID 300/150-100 MG DOSE PACK (SEVERE RENAL DOSE)?

Yes. 1 NADAC-published product shares the same active ingredient, strength, and dosage form. The lowest-priced option, PAXLOVID 300-100 MG DOSE PACK, is $49.2332 per EA — about 63% below PAXLOVID 300/150-100 MG DOSE PACK (SEVERE RENAL DOSE).

Who manufactures PAXLOVID 300/150-100 MG DOSE PACK (SEVERE RENAL DOSE)?

PAXLOVID 300/150-100 MG DOSE PACK (SEVERE RENAL DOSE) (NDC 00069545011) is labeled by Pfizer Inc., and CMS classifies it as a brand product.

Related Drugs

Same classification

No related drugs found.